The real‐world observational prospective study of health outcomes with dulaglutide and liraglutide in patients with type 2 diabetes ( TROPHIES ): Final, 24‐month analysis of time to first significant treatment change, treatment persistence and clinical outcomes
Main finding · Significant treatment changeResult — go to the resultHazard ratio 0.54 95% CI 0.46–0.63Authors' conclusion
Dulaglutide-initiating patients had a longer time spent without any significant treatment change and higher persistence than those initiating liraglutide. Treatment with either glucagon-like peptide-1 receptor agonist yielded similar and clinically meaningful reductions in HbA1c and body weight.
Study context
- Population
- Patients with T2D initiating their first injectable glucose-lowering medication, France, Germany and Italy
- Participants
- 1,014 vs 991
- Exposure
- Dulaglutide vs liraglutide
- Dulaglutiden = 1,014
- Liraglutiden = 991reference
- Outcome
- Time spent on dulaglutide or liraglutide until a significant treatment change
- Follow-up
- 24 months
Methodological detailsreal-world, propensity-score-based inverse probability of treatment weighting (IPTW)
- Real-world
- Propensity-score-based IPTW
Main finding
Significant treatment change
Hazard ratio
0.54
95% CI 0.46–0.63
Events by group
Dulaglutide
28.2%
286 of 1014
Liraglutide
45.2%
448 of 991
As reported in the abstract
Observational data: associations, not effects.
Further findings
HbA1c reduction from baseline · 24 months Dulaglutide −11.80 mmol/mol · Liraglutide −11.91 mmol/mol
%
kg
| Outcome | Dulaglutide | Liraglutide | HR (95% CI) |
|---|---|---|---|
| Persistence with treatment · 24 monthsMore likely persistent with dulaglutide; IPTW analysis | 0.69 (0.56–0.86) | ||
| Weight reduction from baseline · 24 months | −3.5 | −3.3 |
HbA1c reduction from baseline · 24 months
- Similar HbA1c reductions
Weight reduction from baseline · 24 months
- Similar weight reductions
Treatment patterns with other glucose-lowering medication (GLMs)
- Few changes in patterns of treatment with other GLMs in the two cohorts
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →